OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer

Gut. 2022 May;71(5):1043-1044. doi: 10.1136/gutjnl-2021-325551. Epub 2021 Aug 3.

Authors

Junya Arai¹, Ryota Niikura^{2

3}, Yoku Hayakawa², Tomonori Aoki¹, Atsuo Yamada¹, Takashi Kawai³, Mitsuhiro Fujishiro¹

Affiliations

¹ Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.
² Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan yhayakawa-tky@umin.ac.jp niikura-dky@umin.ac.jp.
³ Department of Gastroenterological Endoscopy, Tokyo Medical University, Shinjuku-ku, Japan.

PMID: 34344784
DOI: 10.1136/gutjnl-2021-325551

No abstract available

Keywords: gastric cancer; gastric metaplasia; proton pump inhibition.

Publication types

Letter
Comment

MeSH terms

Helicobacter Infections*
Helicobacter pylori*
Humans
Metaplasia
Proton Pump Inhibitors / adverse effects
Stomach Neoplasms* / chemically induced

Substances

Proton Pump Inhibitors